Evidence map›Paper›PMID 36316302›Full record

ArticleESC heart failure2023

Systemic immune-inflammation index as a prognostic marker for advanced chronic heart failure with renal dysfunction.

Zeyu Wang, Zhen Qin, Ruixia Yuan, Jiacheng Guo, Shuai Xu, Yan Lv, Yanyan Xu, Yongzheng Lu, Jiamin Gao, Fengyi Yu and 6 more

Abstract read
In one paragraph

Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Prognostic value of 9 immune-inflammatory markers for patients with dilated cardiomyopathy: A retrospective study.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Harnessing the lymphatic system.Heart failure reviews · 2025
    Review
  18. Article
  19. Heart failure, inflammation and exercise.International journal of biological sciences · 2025
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Zeyu WangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.ORCID https://orcid.org/0000-0002-3373-900X
Zhen QinDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ruixia YuanClinical Big Data Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiacheng GuoDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Shuai XuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yan LvDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yanyan XuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Yongzheng LuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jiamin GaoDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fengyi YuDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Laiyi TangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Li ZhangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jing BaiDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Xiaolin CuiSchool of Medicine, The Chinese University of Hong Kong, Shenzhen, China.
Jinying ZhangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Junnan TangDepartment of Cardiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

Funding

Excellent Youth Science Foundation of Henan Province 202300410362Henan Province Medical Science and Technology Key Joint Project SBGJ202101012Henan Thousand Talents Program ZYQR201912131National Heart Foundation of New Zealand 1891National Heart Foundation of New Zealand 1896National Natural Science Foundation of China 82170281National Natural Science Foundation of China 82222007National Natural Science Foundation of China U2004203New Zealand Health Research Council 19/779New Zealand Ministry for Business, Employment and Innovation MWF-UOO2103The Chinese University of Hong Kong (Shenzhen) K10120220254
6 · The paper itself

Abstract

aimsWe aim to investigate the correlation between high levels of the systemic immune-inflammation index (SII) and long-term mortality and major cardiovascular adverse events in advanced chronic heart failure patients with renal dysfunction. METHODS AND

resultsSeven hundred seventeen advanced chronic heart failure patients with renal dysfunction, who visited the First affiliated hospital of Zhengzhou University from September 2019 to December 2020, were included. All-cause mortalities (ACM) were selected as primary endpoints and major cardiovascular adverse events (MACEs) as the secondary endpoints. Based on the receiver operating characteristic (ROC) curve and the Youden index, the optimal cut-off values of SII for ACM and MACEs were 1228 and 1406. In the group where ACM were the primary endpoint, patients were categorized into the low-SII group (n = 479) and the high-SII group (n = 238). Patients in the group using MACEs as the secondary endpoint were also categorized into the low-SII groups (n = 514) and the high-SII groups (n = 203). Univariate and multivariate COX regression were used to screen the independent predictors for ACM and MACEs, revealing the relationship between SII levels and endpoints. According to the univariate COX analysis, SII was the risk factor (hazard ratio [HR] = 2.144, 95% confidence interval [CI]: 1.565-2.938, P < 0.001) for the ACM subgroup. It was also the risk factor (HR = 1.625, CI: 1.261-2.905, P < 0.001) for the MACEs subgroup. Multivariate COX regression analysis indicated that the occurrence of ACM and MACEs in high-level SII and low-level SII patients had statistical differences. The incidence of ACM increased by 70.3% (HR = 1.703; 95% CI: 1.200-2.337; P = 0.002) in patients of the high SII level group, the incidence of MACEs increased by 58.3% (HR = 1.583, 95% CI: 1.213-2.065, P = 0.001). Kaplan-Meier (K-M) survival analysis further suggested that patients with a high SII level had an increased risk of having ACM (log-rank P < 0.001) and MACEs (log-rank P < 0.001) within 30 months. SII could be considered as a novel predictor of the occurrence of ACM and MACEs for patients with advanced chronic heart failure and renal dysfunction.

conclusionsThis study suggested that SII is a novel independent predictor of mortality in advanced chronic heart failure patients with renal dysfunction, and it should be considered in current clinical management.

Indexed as

Heart FailureKidney DiseasesHumansInflammationPrognosisProportional Hazards Modelsadvanced chronic heart failureMACEsmortalityprognosisrenal dysfunctionsystemic immune-inflammation index

Identifiers

PMID36316302
PMCPMC9871671

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.